IL-1 binding proteins

US 9,409,986 B2
Filed: 12/18/2013
Issued: 08/09/2016
Est. Priority Date: 05/14/2010
Status: Active Grant

First Claim

Patent Images

1. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises an antigen binding domain, said binding protein capable of binding human IL-1β

, said antigen binding domain comprising six CDRs;

CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, as defined below;

CDR-H1;

X₁-Y-D-M-S (SEQ ID NO;

190), wherein;

X₁is, K or R;

CDR-H2;

Y-X₂-S-X₄-G-G-X₇-G-T-Y-Y-P-D-X₁₄-X₁₅-K-G (SEQ ID NO;

191), wherein;

X₂is I or V;

X₄is S or H;

X₇is G or A;

X₁₄is T or S; and

X₁₅is V or A;

CDR-H3;

G-G-V-X₄-K-G-X₇-F-D-X₁₀(SEQ ID NO;

192), wherein;

X₄is T or Y;

X₇is Y or C; and

X₁₀is V, E, L, M, Q, or Y;

CDR-L1;

R-A-S-G-N-I-X₇-X₈-X₉-L-X₁₁(SEQ ID NO;

193), wherein;

X₇is H, Y, or W;

X₈is N, G, T, Q, E, H, D, or K;

X₉is Y or W; and

X₁₁is T, A, or N;

CDR-L2;

X₁-A-K-X₄-L-X₆-X₇(SEQ ID NO;

194), wherein;

X₁is N, Q, or D;

X₄is T, N, I, E, or S;

X₆is A, M, or E; and

X₇is D, E, S, or A;

andCDR-L3;

Q-X₂-F-W-X₅-X₆-P-X₈-X₉(SEQ ID NO;

195), wherein;

X₂is H or Q;

X₅is S, N, T, K, R, or M;

X₆is I or L;

X₈is Y or A; and

X₉is T, I, and N;

except thatCDR-H2 cannot be Y-I-S-S-G-G-G-G-T-Y-Y-P-D-T-V-K-G (SEQ ID NO;

18);

CDR-H3 cannot be G-G-V-T-K-G-Y-F-D-V (SEQ ID NO;

19);

CDR-L1 cannot be R-A-S-G-N-I-H-N-Y-L-T (SEQ ID NO;

20);

CDR-L2 cannot be N-A-K-T-L-A-D (SEQ ID NO;

21); and

CDR-L3 cannot be Q-H-F-W-S-I-P-Y-T (SEQ ID NO;

22), such that the human IL-1 activity in the human subject suffering from a disorder in which IL-1 activity is detrimental is reduced.

View all claims

2 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

134 Citations

20 Claims

1. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises an antigen binding domain, said binding protein capable of binding human IL-1β
- , said antigen binding domain comprising six CDRs;
  
  CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, as defined below;
  
  CDR-H1;
  
  X₁-Y-D-M-S (SEQ ID NO;
  
  190), wherein;
  
  X₁is, K or R;
  
  CDR-H2;
  
  Y-X₂-S-X₄-G-G-X₇-G-T-Y-Y-P-D-X₁₄-X₁₅-K-G (SEQ ID NO;
  
  191), wherein;
  
  X₂is I or V;
  
  X₄is S or H;
  
  X₇is G or A;
  
  X₁₄is T or S; and
  
  X₁₅is V or A;
  
  CDR-H3;
  
  G-G-V-X₄-K-G-X₇-F-D-X₁₀(SEQ ID NO;
  
  192), wherein;
  
  X₄is T or Y;
  
  X₇is Y or C; and
  
  X₁₀is V, E, L, M, Q, or Y;
  
  CDR-L1;
  
  R-A-S-G-N-I-X₇-X₈-X₉-L-X₁₁(SEQ ID NO;
  
  193), wherein;
  
  X₇is H, Y, or W;
  
  X₈is N, G, T, Q, E, H, D, or K;
  
  X₉is Y or W; and
  
  X₁₁is T, A, or N;
  
  CDR-L2;
  
  X₁-A-K-X₄-L-X₆-X₇(SEQ ID NO;
  
  194), wherein;
  
  X₁is N, Q, or D;
  
  X₄is T, N, I, E, or S;
  
  X₆is A, M, or E; and
  
  X₇is D, E, S, or A;
  
  andCDR-L3;
  
  Q-X₂-F-W-X₅-X₆-P-X₈-X₉(SEQ ID NO;
  
  195), wherein;
  
  X₂is H or Q;
  
  X₅is S, N, T, K, R, or M;
  
  X₆is I or L;
  
  X₈is Y or A; and
  
  X₉is T, I, and N;
  
  except thatCDR-H2 cannot be Y-I-S-S-G-G-G-G-T-Y-Y-P-D-T-V-K-G (SEQ ID NO;
  
  18);
  
  CDR-H3 cannot be G-G-V-T-K-G-Y-F-D-V (SEQ ID NO;
  
  19);
  
  CDR-L1 cannot be R-A-S-G-N-I-H-N-Y-L-T (SEQ ID NO;
  
  20);
  
  CDR-L2 cannot be N-A-K-T-L-A-D (SEQ ID NO;
  
  21); and
  
  CDR-L3 cannot be Q-H-F-W-S-I-P-Y-T (SEQ ID NO;
  
  22), such that the human IL-1 activity in the human subject suffering from a disorder in which IL-1 activity is detrimental is reduced.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- - 2. The method according to claim 1, wherein administering to the subject is by at least one route selected from the group consisting of:
    - parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.
  - 3. The method according to claim 1, further comprising administering at least one additional agent.
  - 4. The method according to claim 3, wherein the at least one additional agent is a therapeutic agent.
  - 5. The method according to claim 4, wherein the therapeutic agent comprises at least one selected from the group consisting of:
    - an inhaled steroid;
      
      a beta-agonist;
      
      a short-acting beta-agonist;
      
      a long-acting beta-agonist;
      
      an antagonist of a leukotriene;
      
      an antagonist of a leukotriene receptor;
      
      ADVAIR™
      
      ;
      
      an IgE inhibitor;
      
      an anti-IgE antibody;
      
      XOLAIR™
      
      ;
      
      a phosphodiesterase inhibitor;
      
      a PDE4 inhibitor;
      
      a xanthine;
      
      an anticholinergic drug;
      
      a mast cell-stabilizing agent;
      
      Cromolyn;
      
      an IL-4 inhibitor;
      
      an IL-5 inhibitor;
      
      an eotaxin/CCR3 inhibitor;
      
      an antagonist of histamine;
      
      an antagonist of histamine receptors including H1, H2, H3, and H4;
      
      an antagonists of prostaglandin D;
      
      an antagonist of prostaglandin D receptors DP1 and CRTH2;
      
      a TNF antagonist;
      
      a soluble fragment of a TNF receptor;
      
      ENBREL®
      
      ;
      
      a TNF enzyme antagonist;
      
      a TNF converting enzyme (TACE) inhibitor;
      
      a muscarinic receptor antagonist;
      
      a TGF-beta antagonist;
      
      an interferon gamma;
      
      a perfenidone;
      
      a chemotherapeutic agent, a methotrexate;
      
      a leflunomide;
      
      a sirolimus (rapamycin) or an analog thereof;
      
      CCI-779;
      
      a COX2 inhibitor;
      
      a cPLA2 inhibitor;
      
      a NSAID;
      
      an immunomodulator;
      
      a p38 inhibitor;
      
      a TPL-2 inhibitor;
      
      a MK-2 inhibitor;
      
      a NFkB inhibitor;
      
      budenoside;
      
      an epidermal growth factor;
      
      a corticosteroid;
      
      cyclosporine;
      
      sulfasalazine;
      
      an aminosalicylate;
      
      6-mercaptopurine;
      
      azathioprine;
      
      metronidazole;
      
      a lipoxygenase inhibitor;
      
      mesalamine;
      
      olsalazine;
      
      balsalazide;
      
      an antioxidants;
      
      a thromboxane inhibitor;
      
      a IL-1 receptor antagonist;
      
      an anti-IL-1β
      
      antibody;
      
      an anti-IL-6 antibody;
      
      a growth factor;
      
      an elastase inhibitor;
      
      a pyridinyl-imidazole compound;
      
      an antibody or agonist of TNF, LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, EMAP-II, GM-CSF, FGF, or PDGF;
      
      an antibody of CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands;
      
      FK506;
      
      rapamycin;
      
      mycophenolate mofetil;
      
      ibuprofen;
      
      prednisolone;
      
      a phosphodiesterase inhibitor;
      
      an adensosine agonist;
      
      an antithrombotic agent;
      
      a complement inhibitor;
      
      an adrenergic agent;
      
      an IRAK inhibitor;
      
      a NIK inhibitor;
      
      an IKK inhibitor;
      
      a p38 inhibitor;
      
      a MAP kinase inhibitors;
      
      an IL-1β
      
      converting enzyme inhibitor;
      
      a TNF-α
      
      converting enzyme inhibitor;
      
      a T-cell signaling inhibitor;
      
      a metalloproteinase inhibitor;
      
      a 6-mercaptopurine;
      
      an angiotensin converting enzyme inhibitor;
      
      a soluble cytokine receptor;
      
      a soluble p55 TNF receptor;
      
      a soluble p75 TNF receptor;
      
      sIL-1RI;
      
      sIL-1RII;
      
      sIL-6R;
      
      an anti-inflammatory cytokine;
      
      IL-4;
      
      IL-10;
      
      IL-11; and
      
      TGF-β
      
      .
  - 6. The method according to claim 4, wherein the therapeutic agent comprises at least one selected from the group consisting of:
    - methotrexate;
      
      6-MP;
      
      azathioprine sulphasalazine;
      
      mesalazine;
      
      olsalazine chloroquinine/hydroxychloroquine;
      
      pencillamine;
      
      aurothiomalate;
      
      azathioprine;
      
      colchicine;
      
      a corticosteroid;
      
      a beta-2 adrenoreceptor agonists;
      
      a xanthine;
      
      cromoglycate;
      
      nedocromil;
      
      ketotifen;
      
      ipratropium and oxitropium;
      
      cyclosporin;
      
      FK506;
      
      rapamycin;
      
      mycophenolate mofetil;
      
      leflunomide;
      
      a NSAID;
      
      a corticosteroid;
      
      a phosphodiesterase inhibitor;
      
      an adensosine agonist;
      
      an antithrombotic agent;
      
      a complement inhibitor;
      
      an adrenergic agent;
      
      an agent which interferes with IKK;
      
      p38 inhibitor;
      
      MAP kinase inhibitors;
      
      an IL-1β
      
      converting enzyme inhibitor;
      
      a TNF-α
      
      converting enzyme (TACE) inhibitor;
      
      a T-cell signaling inhibitor;
      
      metalloproteinase inhibitors;
      
      sulfasalazine;
      
      azathioprine;
      
      a 6-mercaptopurine;
      
      an angiotensin converting enzyme inhibitor;
      
      a soluble cytokine receptor or derivative thereof;
      
      an antiinflammatory cytokine;
      
      celecoxib;
      
      folic acid;
      
      hydroxychloroquine sulfate;
      
      etanercept;
      
      infliximab;
      
      naproxen;
      
      valdecoxib;
      
      sulfasalazine;
      
      methylprednisolone;
      
      meloxicam;
      
      methylprednisolone acetate;
      
      gold sodium thiomalate;
      
      aspirin;
      
      triamcinolone acetonide;
      
      propoxyphene napsylate/apap;
      
      folate;
      
      nabumetone;
      
      diclofenac;
      
      piroxicam;
      
      etodolac;
      
      diclofenac sodium;
      
      oxaprozin;
      
      oxycodone hcl;
      
      hydrocodone bitartrate/apap;
      
      diclofenac sodium/misoprostol;
      
      fentanyl;
      
      anakinra;
      
      human recombinant;
      
      tramadol hcl;
      
      salsalate;
      
      sulindac;
      
      cyanocobalamin/fa/pyridoxine;
      
      acetaminophen;
      
      alendronate sodium;
      
      prednisolone;
      
      morphine sulfate;
      
      lidocaine hydrochloride;
      
      indomethacin;
      
      glucosamine sulf/chondroitin;
      
      amitriptyline HCl;
      
      sulfadiazine;
      
      oxycodone HCl/acetaminophen;
      
      olopatadine HCl;
      
      misoprostol;
      
      naproxen sodium;
      
      omeprazole;
      
      cyclophosphamide;
      
      rituximab;
      
      IL-1 TRAP;
      
      MRA;
      
      CTLA4-IG;
      
      IL-18 BP;
      
      anti-IL-18;
      
      anti-IL15;
      
      BIRB-796;
      
      SCIO-469;
      
      VX-702;
      
      AMG-548;
      
      VX-740;
      
      Roflumilast;
      
      IC-485;
      
      CDC-801; and
      
      Mesopram.
  - 7. The method according to claim 1, comprising CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3wherein the CDR-H1 is an amino acid selected from the group consisting ofresidues 31-35 of SEQ ID NO:
    - 60;
      
      residues 31-35 of SEQ ID NO;
      
      61;
      
      residues 31-35 of SEQ ID NO;
      
      114; and
      
      residues 31-35 of SEQ ID NO;
      
      117;
      
      wherein the CDR-H2 is an amino acid selected from the group consisting ofresidues 50-66 of SEQ ID NO;
      
      60;
      
      residues 50-66 of SEQ ID NO;
      
      71;
      
      residues 50-66 of SEQ ID NO;
      
      105;
      
      residues 50-66 of SEQ ID NO;
      
      113;
      
      residues 50-66 of SEQ ID NO;
      
      123;
      
      residues 50-66 of SEQ ID NO;
      
      131; and
      
      residues 50-66 of SEQ ID NO;
      
      133;
      
      wherein the CDR-H3 is an amino acid selected from the group consisting ofresidues 99-108 of SEQ ID NO;
      
      60 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      61 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      64 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      78 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      87 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      92 (CDR-H3);
      
      residues 99-108 of SEQ ID NO;
      
      104 (CDR-H3); and
      
      residues 99-108 of SEQ ID NO;
      
      140 (CDR-H3);
      
      wherein the CDR-L1 is an amino acid selected from the group consisting ofresidues 24-34 of SEQ ID NO;
      
      59 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      149 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      150 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      151 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      153 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      156 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      159 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      164 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      167 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      174 (CDR-L1);
      
      residues 24-34 of SEQ ID NO;
      
      179 (CDR-L1); and
      
      residues 24-34 of SEQ ID NO;
      
      188 (CDR-L1);
      
      wherein the CDR-L2 is an amino acid selected from the group consisting ofresidues 50-56 of SEQ ID NO;
      
      59 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      149 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      151 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      156 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      167 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      169 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      171 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      175 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      176 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      178 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      180 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      181 (CDR-L2);
      
      residues 50-56 of SEQ ID NO;
      
      185 (CDR-L2); and
      
      residues 50-56 of SEQ ID NO;
      
      187 (CDR-L2);
      
      orwherein the CDR-L3 is an amino acid selected from the group consisting ofresidues 89-97 of SEQ ID NO;
      
      59 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      149 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      150 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      151 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      155 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      160 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      167 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      176 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      181 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      182 (CDR-L3);
      
      residues 89-97 of SEQ ID NO;
      
      183 (CDR-L3); and
      
      residues 89-97 of SEQ ID NO;
      
      188 (CDR-L3).
  - 8. The method according to claim 1, wherein at least three CDRs are from a set of CDRs selected from the group of CDR sets consisting of:
  - 9. The method according to claim 8, comprising CDRs from two CDR sets, wherein said two CDR sets comprise a VH CDR Set selected from the group consisting of CDR Sets 1-23, and a VL CDR Set selected from the group consisting of CDR Sets 24-56.
  - 10. The method according to claim 9, further comprising a human acceptor framework.
  - 11. The method according to claim 10, wherein said human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
    - 7-10, 13-16, 25, 240-316, and 317-381.
  - 12. The method according to claim 10, wherein said human acceptor framework comprises at least one framework region amino acid substitution, wherein the amino acid sequence of the framework is at least 65% identical to the sequence of said human acceptor framework and comprises at least 70 amino acid residues identical to said human acceptor framework.
  - 13. The method according to claim 10, wherein said human acceptor framework comprises at least one framework region amino acid substitution at a key residue, said key residue selected from the group consisting of a residue adjacent to a CDR;
    - a glycosylation site residue;
      
      a rare residue;
      
      a residue capable of interacting with human IL-1β
      
      ;
      
      a residue capable of interacting with a CDR;
      
      a canonical residue;
      
      a contact residue between heavy chain variable region and light chain variable region;
      
      a residue within a Vernier zone; and
      
      a residue in a region that overlaps between a Chothia-defined variable heavy chain CDR1 and a Kabat-defined first heavy chain framework.
  - 14. The method according to claim 13, wherein the key residue by Kabat numbering is selected from the group consisting of:
    - 2H, 4H, 24H, 26H, 27H, 29H, 34H, 35H, 37H, 39H, 44H, 45H, 47H, 48H, 49H, 50H, 51H, 58H, 59H, 60H, 63H, 67H, 69H, 71H, 73H, 76H, 78H, 91H, 93H, 94H, 2L, 4L, 25L, 29L, 27bL, 33L, 34L, 36L, 38L, 43L, 44L, 46L, 47L, 48L, 49L, 55L, 58L, 62L, 64L, 71L, 87L, 89L, 90L, 91L, 94L, and 95L.
  - 15. The method according to claim 10, wherein the binding protein comprises a consensus human variable domain.
  - 16. The method according to claim 9, wherein said binding protein comprises at least one variable domain having an amino acid sequence selected from the group consisting of SEQ ID NOs 59-122 and 124-211.
  - 17. The method according to claim 16, wherein said binding protein comprises two variable domains.
  - 18. The method according to claim 17, wherein said two variable domains comprise amino acid sequences selected from the group consisting of:
  - 19. The method according to claim 9, wherein said two CDR sets comprise CDR Set 5 and CDR Set 56.
  - 20. The method according to claim 16, wherein said at least one variable domain comprises the amino acid sequences of SEQ ID NO:
    - 204 and SEQ ID NO;
      
      205.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Abbvie Incorporated
Original Assignee
Abbvie Incorporated
Inventors
Wu, Chengbin, Ambrosi, Dominic J., Hsieh, Chung-ming, Ghayur, Tariq
Primary Examiner(s)
Wu, Julie

Application Number

US14/133,380
Publication Number

US 20140205562A1
Time in Patent Office

965 Days
Field of Search

None
US Class Current

1/1
CPC Class Codes

A61K 38/00   Medicinal preparations cont...

A61K 39/3955   against proteinaceous mater...

A61K 45/06   Mixtures of active ingredie...

A61K 47/6879   the immunoglobulin having t...

A61K 9/0014   Skin, i.e. galenical aspect...

A61K 9/0019   Injectable compositions; In...

A61K 9/0031   Rectum, anus

A61K 9/0034   Urogenital system, e.g. vag...

A61K 9/0043   Nose

A61K 9/0053   Mouth and digestive tract, ...

A61K 9/006   Oral mucosa, e.g. mucoadhes...

A61K 9/007   Pulmonary tract; Aromatherapy

A61K 9/0085   Brain, e.g. brain implants;...

A61P 1/00   Drugs for disorders of the ...

A61P 1/04   for ulcers, gastritis or re...

A61P 1/14   Prodigestives, e.g. acids, ...

A61P 1/16   for liver or gallbladder di...

A61P 1/18   for pancreatic disorders, e...

A61P 11/00   Drugs for disorders of the ...

A61P 11/02   Nasal agents, e.g. deconges...

A61P 11/04 : for throat disorders

A61P 11/06 : Antiasthmatics

A61P 11/16 : Central respiratory analeptics

A61P 13/02 : of urine or of the urinary ...

A61P 13/08 : of the prostate

A61P 13/12 : of the kidneys

A61P 15/02 : for disorders of the vagina

A61P 15/08 : for gonadal disorders or fo...

A61P 15/10 : for impotence

A61P 17/00 : Drugs for dermatological di...

A61P 17/02 : for treating wounds, ulcers...

A61P 17/04 : Antipruritics

A61P 17/06 : Antipsoriatics

A61P 17/08 : Antiseborrheics

A61P 17/14 : for baldness or alopecia

A61P 19/00 : Drugs for skeletal disorders

A61P 19/02 : for joint disorders, e.g. a...

A61P 19/06 : Antigout agents, e.g. antih...

A61P 19/10 : for osteoporosis

A61P 21/00 : Drugs for disorders of the ...

A61P 21/02 : Muscle relaxants, e.g. for ...

A61P 21/04 : for myasthenia gravis

A61P 25/00 : Drugs for disorders of the ...

A61P 25/04 : Centrally acting analgesics...

A61P 25/06 : Antimigraine agents

A61P 25/14 : for treating abnormal movem...

A61P 25/16 : Anti-Parkinson drugs

A61P 25/18 : Antipsychotics, i.e. neurol...

A61P 25/22 : Anxiolytics

A61P 25/24 : Antidepressants

A61P 25/28 : for treating neurodegenerat...

A61P 25/30 : for treating abuse or depen...

A61P 25/32 : Alcohol-abuse

A61P 27/02 : Ophthalmic agents

A61P 27/14 : Decongestants or antiallergics

A61P 29/00 : Non-central analgesic, anti...

A61P 3/00 : Drugs for disorders of the ...

A61P 3/02 : Nutrients, e.g. vitamins, m...

A61P 3/06 : Antihyperlipidemics

A61P 3/08 : for glucose homeostasis pan...

A61P 3/10 : for hyperglycaemia, e.g. an...

A61P 3/14 : for calcium homeostasis vit...

A61P 31/00 : Antiinfectives, i.e. antibi...

A61P 31/04 : Antibacterial agents

A61P 31/06 : for tuberculosis

A61P 31/08 : for leprosy

A61P 31/10 : Antimycotics

A61P 31/12 : Antivirals

A61P 31/14 : for RNA viruses

A61P 31/16 : for influenza or rhinoviruses

A61P 31/18 : for HIV

A61P 31/20 : for DNA viruses

A61P 33/00 : Antiparasitic agents

A61P 33/02 : Antiprotozoals, e.g. for le...

A61P 33/06 : Antimalarials

A61P 33/08 : for Pneumocystis carinii

A61P 35/00 : Antineoplastic agents

A61P 35/02 : specific for leukemia

A61P 37/00 : Drugs for immunological or ...

A61P 37/02 : Immunomodulators

A61P 37/04 : Immunostimulants

A61P 37/06 : Immunosuppressants, e.g. dr...

A61P 37/08 : Antiallergic agents antiast...

A61P 39/02 : Antidotes

A61P 43/00 : Drugs for specific purposes...

A61P 5/00 : Drugs for disorders of the ...

A61P 5/14 : of the thyroid hormones, e....

A61P 5/16 : for decreasing, blocking or...

A61P 5/18 : of the parathyroid hormones

A61P 5/48 : of the pancreatic hormones

A61P 5/50 : for increasing or potentiat...

A61P 7/02 : Antithrombotic agents; Anti...

A61P 7/04 : Antihaemorrhagics; Procoagu...

A61P 7/06 : Antianaemics

A61P 7/08 : Plasma substitutes; Perfusi...

A61P 7/10 : Antioedematous agents; Diur...

A61P 9/00 : Drugs for disorders of the ...

A61P 9/04 : Inotropic agents, i.e. stim...

A61P 9/06 : Antiarrhythmics

A61P 9/08 : Vasodilators for multiple i...

A61P 9/10 : for treating ischaemic or a...

A61P 9/12 : Antihypertensives

A61P 9/14 : Vasoprotectives; Antihaemor...

C07K 14/545 : IL-1

C07K 16/245 : IL-1

C07K 16/468 : Immunoglobulins having two ...

C07K 2317/24 : containing regions, domains...

C07K 2317/31 : multispecific

C07K 2317/33 : Crossreactivity, e.g. for s...

C07K 2317/56 : variable (Fv) region, i.e. ...

C07K 2317/565 : Complementarity determining...

C07K 2317/64 : comprising a combination of...

C07K 2317/76 : Antagonist effect on antige...

C07K 2317/92 : Affinity (KD), association ...

G01N 2333/545 : IL-1

G01N 2800/00 : Detection or diagnosis of d...

G01N 33/6869 : Interleukin

Y02A 50/30 : Against vector-borne diseas...

View All

IL-1 binding proteins

First Claim

2 Assignments

0 Petitions

Accused Products

Abstract

134 Citations

20 Claims

Specification

Use Cases

Quick Links

Others

IL-1 binding proteins

First Claim

2 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

134 Citations

20 Claims

Specification

Subscription Required

Use Cases

Quick Links

Others